Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €37.40 EUR
Change Today -0.468 / -1.24%
Volume 0.0
ILR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (ILR) Snapshot

Open
€38.35
Previous Close
€37.87
Day High
€39.06
Day Low
€37.40
52 Week High
04/13/15 - €49.00
52 Week Low
10/8/14 - €18.10
Market Cap
2.7B
Average Volume 10 Days
16.6
EPS TTM
--
Shares Outstanding
72.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPAX LABORATORIES INC (ILR)

impax laboratories inc (ILR) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (ILR) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

1,061 Employees
Last Reported Date: 02/26/15
Founded in 1993

impax laboratories inc (ILR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $552.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $446.2K
President of Impax Pharmaceuticals
Total Annual Compensation: $515.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $484.2K
Senior Vice President of Technical Operations
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

impax laboratories inc (ILR) Key Developments

Avanir Pharmaceuticals, Inc. Announces Appeals Court Ruling in NUEDEXTA Patent Case in US Against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc

Avanir Pharmaceuticals, Inc. has announced that a panel of the US Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA, a FDA-approved product for the treatment of Pseudobulbar affect, or PBA. The decision confirms patent protection for NUEDEXTA, or the 282 patent and the 484 patent, until 2026 in the US. The Appeals Court ruling affirmed the April 2014 decision upholding the '282' and '484' patents' validity by the US District Court for the District of Delaware in a lawsuit brought by Avanir against the Par Pharmaceuticals, Inc. and Impax Laboratories, Inc.

Impax Laboratories Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

Impax Laboratories Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues were $214,182,000 against $188,121,000 a year ago. The increase was primarily due to the addition of product revenues from the company's acquisition on March 9, 2015 of Tower Holdings Inc. and Lineage Therapeutics Inc., and sales from new brand and generic product launched in 2015. Income from operations was $18,053,000 against $53,936,000 a year ago. Loss before income taxes was $4,548,000 against income before income taxes of $54,425,000 a year ago. Net loss was $1,852,000 against net income of $35,071,000 a year ago. Net loss diluted per share was $0.03 against net income of $0.50 a year ago. Adjusted net income was $24.446 million against $42.294 million a year ago. Net income adjusted per diluted share was $0.34 against $0.60 a year ago. EBITDA was $9.759 million against $59.661 million a year ago. Adjusted EBITDA was $59.835 million against $76.222 million a year ago. Adjusted earnings per diluted share decreased $0.34 in the second quarter of 2015 compared to $0.60 last year. This decrease was primarily attributable to the loss of $49 million of high-margin generic RENVELA sales, the loss of approximately $9 million of gross profit from third party profit share and milestone payments, a decline in gross profit earned on generic digoxin due to additional competition, higher interest expense of $6 million and a higher adjusted tax rate. The adjusted gross margin was 81% up from 31% in last year's second quarter. The increase in specialty pharma sales in second quarter 2015 drove a $33 million improvement and adjusted operating income. For the six months, the company reported total revenues were $357,278,000 against $306,839,000 a year ago. Income from operations was $11,205,000 against $62,167,000 a year ago. Loss before income taxes was $15,253,000 against income before income taxes of $63,055,000 a year ago. Net loss was $8,185,000 against net income of $41,496,000 a year ago. Net loss diluted per share was $0.12 against net income of $0.59 a year ago. Net cash used in operating activities was $32,585,000 against net cash provided by operating activities of $12,420,000 a year ago. Purchases of property, plant and equipment was $8,482,000 against $18,271,000 a year ago. Adjusted net income was $30.792 million against $58.775 million a year ago. Net income adjusted per diluted share was $0.43 against $0.84 a year ago. EBITDA was $8.903 million against $73.553 million a year ago. Adjusted EBITDA was $83.824 million against $111.001 million a year ago. The company provided earnings guidance for the full year 2015. For the period, the company expected adjusted gross margins as a percentage of total revenue are expected to be in the low 50% range (previously mid 50% range). The company expected adjusted interest expense of approximately $14 million, capital expenditures of approximately $45 million to $50 million and effective tax rate of approximately 34% to 36% on a GAAP basis, which assumes that the U.S. R&D tax credit is renewed for 2015.

Impax Laboratories Inc. Enters into a Senior Secured Revolving Credit Facility of Up to $100 Million

On August 4, 2015, Impax Laboratories Inc. entered into a senior secured revolving credit facility of up to $100 million, pursuant to a credit agreement, dated as of August 4, 2015, by and among the Company, the lenders party thereto from time to time and Royal Bank of Canada, as administrative agent and collateral agent (the “Revolving Credit Facility Agreement”). The Revolving Credit Facility is available for working capital and other general corporate purposes. Borrowings under the Revolving Credit Facility will accrue interest at a rate equal to LIBOR or the base rate, plus an applicable margin. The applicable margin may be increased or reduced by 0.75% based on the company’s total net leverage ratio. The Revolving Credit Facility will mature on August 4, 2020. No borrowings have been drawn from the Revolving Credit Facility to date. Up to $12.5 million of the Revolving Credit Facility is available for issuances of letters of credit and any such issuance of letters of credit will reduce the amount available under the Revolving Credit Facility on a dollar-for-dollar basis. The Company is required to pay a commitment fee to the lenders on the average daily unused portion of the Revolving Credit Facility at an initial rate of 0.375% per annum. The commitment fee rate may be increased or reduced by 0.125% based on the Company’s total net leverage ratio.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILR:GR €37.40 EUR -0.468

ILR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $41.03 USD -0.18
BTG PLC 631.00 GBp +8.50
Prestige Brands Holdings Inc $46.89 USD +0.27
Medicines Co/The $33.64 USD +1.89
USANA Health Sciences Inc $145.50 USD -3.42
View Industry Companies
 

Industry Analysis

ILR

Industry Average

Valuation ILR Industry Range
Price/Earnings 100.0x
Price/Sales 4.5x
Price/Book 3.0x
Price/Cash Flow 399.6x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit www.impaxlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.